TipRanks
Go Ultimate55% OFF

Innate Pharma (IPHA) Stock Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

IPHA Analyst Ratings

Strong Buy
3Ratings
3Buy0Hold0Sell
Based on 3 analysts giving stock ratings to Innate Pharma in the past 3 months

IPHA Stock 12 Month Forecast

$6.67▲(356.62% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Innate Pharma in the last 3 months. The average price target is $6.67 with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 356.62% change from the last price of $1.46.
Highest Price Target$9.00Average Price Target$6.67Lowest Price Target$4.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for IPHA
Analyst ProfileExpert FirmPrice TargetPositionUpside / DownsideActionDateFollowArticle
H.C. Wainwright$7buy379.45%UpsideReiterated10/01/26
BTIG$9buy516.44%UpsideReiterated09/17/26
Leerink Partners$3→$4buy173.97%UpsideUpgraded08/11/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innate Pharma

3 Months
Daina Graybosch
Daina GrayboschLeerink Partners
Success Rate8/24 ratings generated profit
33%
Average Return
-5.03%

Copying Daina Graybosch's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -5.03% per trade.

1 Year
Daina Graybosch
Daina GrayboschLeerink Partners
Success Rate6/24 ratings generated profit
25%
Average Return
-15.92%

Copying Daina Graybosch's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -15.92% per trade.

2 Years
Daina Graybosch
Daina GrayboschLeerink Partners
Success Rate2/24 ratings generated profit
8%
Average Return
-23.74%

Copying Daina Graybosch's trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -23.74% per trade.

IPHA Analyst Recommendation Trends

02468Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
Monthly rating counts for IPHA
RatingMay 26Jun 26Jul 26Aug 26Sep 26
Strong Buy43477
Buy00000
Hold00000
Sell00000
Strong Sell00000
total43477

In the current month, IPHA has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IPHA average Analyst price target in the past 3 months is 6.67.

IPHA Financial Forecast

$-2$-1.5$-1$-0.5$0Q2 2025Q2 2026Q4 2026
High$-0.29
Consensus$-0.29
Low$-0.29

IPHA Earnings Forecast

Next quarter’s earnings estimate for IPHA is -$0.29 with a range of -$0.29 to -$0.29. The previous quarter’s EPS was -$0.24. IPHA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.

$1.3M$2.1M$3M$3.8M$4.7MQ2 2025Q2 2026Q4 2026
High$2.91M
Consensus$2.91M
Low$2.91M

IPHA Sales Forecast

Next quarter’s sales forecast for IPHA is $2.91M with a range of $2.91M to $2.91M. The previous quarter’s sales results were $3.63M. IPHA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.

IPHA Stock Forecast FAQ

What is IPHA’s average 12-month price target, according to analysts?
Based on analyst ratings, Innate Pharma’s 12-month average price target is $6.67.
What is IPHA’s upside potential, based on the analysts’ average price target?
Innate Pharma has 356.62% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IPHA a Buy, Sell or Hold?
Innate Pharma has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Innate Pharma’s price target?
The average price target for Innate Pharma is $6.67. This is based on 3 12-month price targets, issued in the past 3 months. The highest analyst price target is $9.00, the lowest forecast is $4.00. The average price target represents a 356.62% increase from the current price of $1.46.
What do analysts say about Innate Pharma?
Innate Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Street analysts.
How can I buy shares of IPHA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.